Cancer blood clot treatment costs under the microscope

This study looked back at health insurance data to compare the total healthcare costs for cancer patients who developed dangerous blood clots (VTE). Researchers analyzed over 7,300 patients to see if treatment with the drug apixaban was associated with different costs than treatment with low molecular weight heparin (LMWH). The goal was to understand the financial impact of these treatments, including costs for hospital stays, doctor visits, and managing side effects like bleeding.